GlassScriptPhysician profile
Gurkiran Dhindsa
NPI 1750543518
$3,784.33
in general payments reported to CMS, 2019-2025
32 companies · $2,006 in 2025
The $2,006 reported for 2025 was more than what 76% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $19.92 · 2022: $74.58 · 2023: $399 · 2024: $1,053 · 2025: $2,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380 · Gift: $59.40 · Entertainment: $18.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.33 |
| Gift | $59.40 |
| Entertainment | $18.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $372.97 | 2022-2025 | |
| Lilly USA, LLC | $362.29 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Abbott Laboratories | $349.71 | 2019-2025 | Freestyle Libre 3, Eterna |
| Corcept Therapeutics | $270.76 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $252.29 | 2023-2025 | |
| Beta Bionics, INC. | $239.80 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Mannkind Corporation | $218.64 | 2023-2025 | Afrezza |
| Dexcom, INC. | $206.41 | 2023-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $201.23 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Amgen INC. | $168.13 | 2023-2025 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $155.59 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $138.93 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $96.02 | 2023-2025 | Ubrelvy, Vraylar |
| Sanofi-Aventis U.S. LLC | $93.03 | 2024-2025 | |
| Sequel Med Tech, LLC | $92.24 | 2025 | Twiist |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $86.49 | 2022-2024 | Minimed 780g |
| Globus Medical, INC. | $82.48 | 2025 | Senza |
| Ascendis Pharma Endocrinology INC | $69.03 | 2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.90 | 2023-2025 | Jardiance |
| Sandoz INC. | $46.64 | 2025 | Jubbonti |
| Radius Health, INC. | $31.98 | 2025 | Tymlos |
| Verity Pharmaceuticals INC. | $27.64 | 2025 | Tlando |
| Nevro Corp. | $25.27 | 2023 | Senza |
| Merck Sharp & Dohme LLC | $19.77 | 2023 | Verquvo, Belsomra, Steglatro |
| Optos, INC. | $18.43 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Kyowa Kirin, INC. | $17.42 | 2024 | Crysvita |
| Astrazeneca Pharmaceuticals LP | $16.85 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $15.85 | 2024 | |
| Medtronic Minimed, INC. | $14.85 | 2019 | |
| Itamar Medical INC | $14.38 | 2025 | Watchpatone |
| Neurocrine Biosciences, INC. | $14.18 | 2024 | |
| Amneal Pharmaceuticals LLC | $14.13 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurkiran Dhindsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.